KRAS and lung carcinoma: The comutation of STK11/LKB1 was reported to have higher KEAP1 mutational inactivation and fewer immune cells, while the comutation of TP53 was associated with higher inflammatory markers and longer relapsed free survival in KRAS-mutated lung cancer [37].